KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Common Equity (2016 - 2025)

Historic Common Equity for Resmed (RMD) over the last 16 years, with Q4 2025 value amounting to $6.3 billion.

  • Resmed's Common Equity rose 2032.87% to $6.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $6.3 billion, marking a year-over-year increase of 2032.87%. This contributed to the annual value of $6.0 billion for FY2025, which is 2269.34% up from last year.
  • Resmed's Common Equity amounted to $6.3 billion in Q4 2025, which was up 2032.87% from $6.1 billion recorded in Q3 2025.
  • In the past 5 years, Resmed's Common Equity ranged from a high of $6.3 billion in Q4 2025 and a low of $2.7 billion during Q1 2021
  • Its 5-year average for Common Equity is $4.3 billion, with a median of $4.2 billion in 2023.
  • Its Common Equity has fluctuated over the past 5 years, first soared by 980.29% in 2021, then skyrocketed by 2381.35% in 2023.
  • Resmed's Common Equity (Quarter) stood at $3.1 billion in 2021, then rose by 18.83% to $3.7 billion in 2022, then grew by 19.9% to $4.5 billion in 2023, then rose by 17.21% to $5.3 billion in 2024, then grew by 20.33% to $6.3 billion in 2025.
  • Its Common Equity stands at $6.3 billion for Q4 2025, versus $6.1 billion for Q3 2025 and $6.0 billion for Q2 2025.